| Literature DB >> 36101804 |
Yunpeng Ma1, Yinzun Qi1, Qiang Li1, Shuangxiong Zhu1, Wenjie Zhao1, Yu Zhang1.
Abstract
In order to investigate the expression levels of Lipoprotein A (LPa), B-type Natriuretic Peptide (BNP) and Monocyte chemoattractor Protein-1 (McP-1) in serum of patients with coronary heart disease (CHD) are used to detect significance and to analyze the correlation between these indicators and parameters of echocardiography. The clinical data of 132 CHD patients in our hospital from January 2021 to October 2021 are retrospectively analyzed and included in the CHD group. Another 100 healthy people who came to our hospital for general physical examination were selected as the control group. The expressions of Serum McP-1 and BNP are detected by the ELISA. The expression of Serum LPa is detected by immunoturbidimetry, and the expressions of SERUM McP-1, BNP, and LPa are compared between the two groups. The experiments show that the expressions of McP-1, BNP, and LPa in serum of control group are significantly lower than those of the CHD group (P < 0.05). Echocardiography results show that left ventricular ejection fraction (LVEF) in CHD group is significantly lower than that in control group, but left ventricular end-systolic volume (LVESV) and left ventricular end-diastolic volume (LVEDV) are significantly higher than those in control group (P < 0.05).Entities:
Mesh:
Substances:
Year: 2022 PMID: 36101804 PMCID: PMC9440810 DOI: 10.1155/2022/5165203
Source DB: PubMed Journal: Contrast Media Mol Imaging ISSN: 1555-4309 Impact factor: 3.009
Baseline data.
| CHD group ( | Control group ( |
|
| |
|---|---|---|---|---|
| Age (years) | 56.52 ± 6.31 | 57.21 ± 6.17 | −0.833 | 0.406 |
|
| ||||
|
| 0.571 | 0.450 | ||
| Man | 74 (56.06%) | 61 (61.00%) | ||
| Woman | 58 (43.94%) | 39 (39.00%) | ||
| BMI (kg/m2) | 23.41 ± 2.19 | 23.43 ± 2.18 | −0.069 | 0.945 |
|
| ||||
|
| 0.323 | 0.570 | ||
| Y | 81 (61.36%) | 65 (65.00%) | ||
| N | 51 (38.64%) | 35 (35.00%) | ||
|
| ||||
|
| 0.365 | 0.546 | ||
| Y | 78 (59.09%) | 63 (63.00%) | ||
| N | 54 (40.91%) | 37 (37.00%) | ||
The serum levels of McP-1, BNP, and LPa.
| Group |
| MCP-1 (pg/ml) | BNP (pg/ml) | LPa (mmol/L) |
|---|---|---|---|---|
| CHD group | 132 | 136.73 ± 24.43 | 87.73 ± 21.25 | 31.25 ± 6.02 |
| Control group | 100 | 102.37 ± 16.33 | 59.46 ± 11.37 | 20.63 ± 5.52 |
|
| 12.154 | 12.056 | 13.779 | |
|
| <0.001 | <0.001 | <0.001 |
Differences in echocardiography parameters.
| Group |
| LVEF (%) | LVESV (ml) | LVEDV (ml) |
|---|---|---|---|---|
| CHD group | 132 | 45.32 ± 4.28 | 93.35 ± 18.42 | 139.63 ± 14.64 |
| Control group | 100 | 61.35 ± 5.35 | 61.29 ± 16.44 | 128.45 ± 12.31 |
|
| −25.348 | 13.744 | 6.162 | |
|
| <0.001 | <0.001 | <0.001 |
Relationship between McP-1, BNP, LPa, and LVEF.
|
| ||
|---|---|---|
|
|
| |
| MCP-1 (pg/ml) | −0.657 | <0.001 |
| BNP (pg/ml) | −0.719 | <0.001 |
| LPa (mmol/L) | −0.702 | <0.001 |
Relationship between McP-1, BNP, LPa, and LVEDV.
|
| ||
|---|---|---|
|
|
| |
| MCP-1 (pg/ml) | 0.526 | <0.001 |
| BNP (pg/ml) | 0.572 | <0.001 |
| LPa (mmol/L) | 0.516 | <0.001 |
Relationship between McP-1, BNP, LPa, and LVESV.
|
| ||
|---|---|---|
|
|
| |
| MCP-1 (pg/ml) | 0.568 | <0.001 |
| BNP (pg/ml) | 0.573 | <0.001 |
| LPa (mmol/L) | 0.561 | <0.001 |
Figure 1Relationship between McP-1, BNP, LPa, and LVEF: (a) relationship between McP-and LVEF; (b) relationship between BNP and LVEF; and (c) relationship between LPa and LVEF.
Figure 2Relationship between McP-1, BNP, LPa, and LVEDV: (a) relationship between McP-1 and LVEDV; (b) relationship between BNP and LVEDV; and (c) relationship between LPa and LVEDV.
Figure 3Relationship between McP-1, BNP, LPa, and LVESV: (a) relationship between McP-1 and LVESV; (b) relationship between BNP and LVESV; and (c) relationship between LPa and LVESV.
Diagnostic efficiency of each index.
| 95%CI | Sensitivity (%) | Specificity (%) | AUC | Cutoff value | |
|---|---|---|---|---|---|
| The joint detection | 0.827–0.968 | 88.40 | 86.30 | 0.898 | |
| LVEF | 0.777–0.933 | 83.20 | 81.20 | 0.803 | 50.00% |
| MCP-1 | 0.650–0.875 | 76.30 | 69.40 | 0.763 | 112.45 |
| BNP | 0.605–0.833 | 77.30 | 71.20 | 0.719 | 71.24 |
| LPa | 0.586–0.812 | 70.30 | 68.30 | 0.699 | 25.31 |
Figure 4ROC curve to evaluate the diagnostic efficacy of combined assays.